Journal ArticleDOI
Fulvestrant ('Faslodex')--a new treatment option for patients progressing on prior endocrine therapy.
C Morris,A Wakeling +1 more
Reads0
Chats0
TLDR
Fulvestrant has recently gained US Food and Drug Administration approval for the treatment of hormone receptor-positive metastatic breast cancer in postmenopausal women with disease progression following antiestrogen therapy and these new hormonal treatments expand the choice of endocrine therapy for women with advanced breast cancer.Abstract:
Since its introduction more than 30 years ago, tamoxifen has been the most widely used endocrine therapy for the treatment of women with advanced breast cancer. More recently, a number of alternative endocrine treatments have been developed, including several selective estrogen receptor modulators (SERMs), aromatase inhibitors (AIs) and, most recently, fulvestrant ('Faslodex'). Fulvestrant is an estrogen receptor (ER) antagonist, which, unlike the SERMs, has no known agonist (estrogenic) effect and downregulates the ER protein. Tamoxifen is effective and well tolerated, although the non-steroidal AIs, anastrozole and letrozole, are more effective treatments for advanced disease than tamoxifen. Fulvestrant has recently gained US Food and Drug Administration approval for the treatment of hormone receptor-positive metastatic breast cancer in postmenopausal women with disease progression following antiestrogen therapy. In two global phase III clinical trials fulvestrant was at least as effective and as equally well tolerated as anastrozole for the treatment of postmenopausal women with advanced and metastatic breast cancer. In a retrospective analysis of the combined data from these trials, mean duration of response was significantly greater for fulvestrant compared with anastrozole. These new hormonal treatments expand the choice of endocrine therapy for women with advanced breast cancer and offer new options for sequencing and combining treatments.read more
Citations
More filters
Journal ArticleDOI
Androgen receptor is targeted to distinct subcellular compartments in response to different therapeutic antiandrogens.
Hayley C. Whitaker,Sarah Hanrahan,Nick Totty,Simon C. Gamble,Jonathan Waxman,Andrew C.B. Cato,Helen C. Hurst,Charlotte L. Bevan +7 more
TL;DR: The first study of the localization of wild-type AR following expression at physiologic relevant levels in prostate cells and treatment with androgen and antiandrogen reveals that not all antiandrogens work via the same mechanism and suggest that an informed sequential treatment regime may benefit prostate cancer patients.
Journal ArticleDOI
What is known about melatonin, chemotherapy and altered gene expression in breast cancer (Review)
Carlos Manuel Martínez Campa,Javier Menéndez Menéndez,Carolina Alonso González,Alicia González,Virginia Álvarez‑García,Samuel Cos +5 more
TL;DR: The latest findings regarding melatonin molecular actions when concomitantly administered with either radiotherapy or chemotherapy in cancer were reviewed, with a particular focus on hormone-dependent breast cancer.
Journal ArticleDOI
ICI 182,780 has agonistic effects and synergizes with estradiol-17 beta in fish liver, but not in testis
Patrícia Pinto,Pratap B Singh,João B. Condeça,Helena R Teodósio,Deborah M. Power,Adelino V.M. Canario +5 more
TL;DR: It is demonstrated that ICI has agonistic effects on several typical estrogenic responses in fish, but its actions are tissue-specific.
Journal ArticleDOI
Intermittent high dose scheduling of AZD8835, a novel selective inhibitor of PI3Kα and PI3Kδ, demonstrates treatment strategies for PIK3CA-dependent breast cancers
Kevin Hudson,Urs Hancox,Cath Trigwell,Robert McEwen,Urszula M. Polanska,Myria Nikolaou,Pablo Morentin Gutierrez,Alvaro Avivar-Valderas,Oona Delpuech,Phillippa Dudley,Lyndsey Hanson,Rebecca Ellston,Alys Jones,Marie Cumberbatch,Sabina Cosulich,Lara Ward,Francisco Cruzalegui,Stephen Green +17 more
TL;DR: AZD8835 IHDS delivers strong antitumor efficacy in a range of combination settings and provides a promising alternative to continuous dosing to optimize the therapeutic index in patients and its alternative approach of intermittent high-dose scheduling (IHDS) was explored given observations that higher exposures achieved greater pathway inhibition and induced apoptosis.
Journal ArticleDOI
Cediranib in combination with fulvestrant in hormone-sensitive metastatic breast cancer: a randomized Phase II study.
David M. Hyams,Arlene Chan,Celia de Oliveira,Raymond Snyder,Jeferson Vinholes,M. William Audeh,Victor M. Alencar,Janine Lombard,Bijoyesh Mookerjee,Bijoyesh Mookerjee,John Xu,Kathryn H. Brown,P Klein +12 more
TL;DR: Cediranib plus fulvestrant may demonstrate clinical activity in this population of hormone-sensitive metastatic breast cancer, but cedIRanib 45 mg was not sufficiently well tolerated and Investigation of lower doses of cedirAnib plus hormonal/chemotherapy could be considered.
References
More filters
Journal ArticleDOI
The Functional Assessment of Cancer Therapy scale: development and validation of the general measure.
David Cella,David S. Tulsky,G Gray,Bernie Sarafian,E Linn,Amy E. Bonomi,M Silberman,Suzanne B. Yellen,Patsy Winicour,J Brannon +9 more
TL;DR: The FACT-G meets or exceeds all requirements for use in oncology clinical trials, including ease of administration, brevity, reliability, validity, and responsiveness to clinical change.
Journal ArticleDOI
Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial.
TL;DR: Anastrozole is an effective and well tolerated endocrine option for the treatment of postmenopausal patients with hormone-sensitive early breast cancer and longer follow-up is required before a final benefit:risk assessment can be made.
Journal Article
A potent specific pure antiestrogen with clinical potential.
TL;DR: The properties of ICI 182,780 identify this pure antiestrogen as a prime candidate with which to evaluate the potential therapeutic benefits of complete estrogen withdrawal in endocrine-responsive human breast cancer.
Journal ArticleDOI
Endometrial Cancer in Tamoxifen-Treated Breast Cancer Patients: Findings From the National Surgical Adjuvant Breast and Bowel Project (NSABP) B-14
TL;DR: Risk of endometrial cancer increases following tamoxifen therapy for invasive breast cancer; however, net benefit greatly outweighs risk, and tamoxIFen treatment for breast cancer should continue.
Journal ArticleDOI
Superior Efficacy of Letrozole Versus Tamoxifen as First-Line Therapy for Postmenopausal Women With Advanced Breast Cancer: Results of a Phase III Study of the International Letrozole Breast Cancer Group
Henning T. Mouridsen,Mikhail Gershanovich,Yan Sun,Ramon Perez-Carrion,Corrado Boni,Alain Monnier,Justus Apffelstaedt,Robert S. Smith,Harm Sleeboom,Fritz Jänicke,Anna Pluzanska,Magdolna Dank,Dominique Becquart,Poonamalle P. Bapsy,Eeva Salminen,Raymond Snyder,Mercedes Lassus,J. Arnold Verbeek,Beatrix Staffler,H. A. Chaudri-Ross,Margaret Dugan +20 more
TL;DR: Letrozole was significantly superior to tamoxifen in TTP, TTF, ORR, and clinical benefit rate, and its results support its use as first-line endocrine therapy in postmenopausal women with advanced breast cancer.